Antimicrobial

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

Antimicrobial is one of 42 small molecule programs targeting Osteomyelitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteomyelitisActive, not recruiting

OsteomyelitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Osteomyelitis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Approved

1 2

Azulfidine

Pfizer

Approved

1 3

Mycobutin

Avelox

Biaxin

Maxipime

Zyvox

Priftin

Cipro

Acanya

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prosthetic-joint Infection1 trial

Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital

Unknown status·—··NCT05239312·90 enrolled

Osteomyelitis1 trial

Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization

Completed·UUniversity of Sao Paulo··NCT03559530·262 enrolled

Urinary Tract Infection1 trial

Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter Urinary Tract Infections.

Withdrawn·UUnity Health Toronto·Phase 3·NCT00795470

Clinical Trial1 trial

The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process: A Randomized Controlled Clinical Trial

Active, not recruiting·KKuwait University·Phase 4·NCT06894667·40 enrolled

Bloodstream Infection1 trial

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01539343·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Antimicrobial. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antimicrobial compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antimicrobial. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Antimicrobial

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prosthetic-joint Infection1 trial

Osteomyelitis1 trial

Urinary Tract Infection1 trial

Clinical Trial1 trial

Bloodstream Infection1 trial

References

Drug Info

Quick Facts

Related News